Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy M Frech

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
Rheumatology (Oxford, England)|October 28, 2017
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosisMichael B Arnold, Dinesh Khanna, Christopher P Denton, et al.
Journal of Scleroderma and Related Disorders|February 2, 2019
Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group ReportJohn D Pauling, Tracy M Frech, Michael Hughes, et al.
Annals of the Rheumatic Diseases|October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 25, 2022
Three Distinct Transcriptional Profiles of Monocytes Associate with Disease Activity in Scleroderma PatientsHadijat-Kubura M Makinde, Julia L M Dunn, Gaurav Gadhvi, et al.
The Lancet. Rheumatology|April 3, 2025
Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort studyMonique Hinchcliff, Dinesh Khanna, Enrico De Lorenzis, et al.
Lancet (London, England)|May 10, 2016
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trialDinesh Khanna, Christopher P Denton, Angelika Jahreis, et al.
Clinical and Experimental Rheumatology|December 3, 2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registryLorinda Chung, Robert M Fairchild, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|November 27, 2019
Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profileBrian Skaug, Dinesh Khanna, William R Swindell, et al.
Rheumatology (Oxford, England)|April 20, 2023
CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilizationSarah Luebker, Tracy M Frech, Shervin Assassi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
Rheumatology (Oxford, England)|October 28, 2017
Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosisMichael B Arnold, Dinesh Khanna, Christopher P Denton, et al.
Journal of Scleroderma and Related Disorders|February 2, 2019
Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group ReportJohn D Pauling, Tracy M Frech, Michael Hughes, et al.
Annals of the Rheumatic Diseases|October 26, 2017
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)Dinesh Khanna, Christopher P Denton, Celia J F Lin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 25, 2022
Three Distinct Transcriptional Profiles of Monocytes Associate with Disease Activity in Scleroderma PatientsHadijat-Kubura M Makinde, Julia L M Dunn, Gaurav Gadhvi, et al.
The Lancet. Rheumatology|April 3, 2025
Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort studyMonique Hinchcliff, Dinesh Khanna, Enrico De Lorenzis, et al.
Lancet (London, England)|May 10, 2016
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trialDinesh Khanna, Christopher P Denton, Angelika Jahreis, et al.
Clinical and Experimental Rheumatology|December 3, 2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registryLorinda Chung, Robert M Fairchild, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|November 27, 2019
Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profileBrian Skaug, Dinesh Khanna, William R Swindell, et al.
Rheumatology (Oxford, England)|April 20, 2023
CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilizationSarah Luebker, Tracy M Frech, Shervin Assassi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
Pageof 11